Globalstar vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Globalstar trades at $82.43 (market cap $10.68B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B). The key difference: Globalstar and Dr. Reddy's Laboratories Ltd Common Stock are close in size by market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Globalstar pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 23 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| GSAT | RDY | |
|---|---|---|
Market Cap | $10.68B | $10.61B |
Volume | 642,471 | 3,738,869 |
Sector | Media | Health |
52-Week High | $84.43 | $15.38 |
52-Week Low | $41.54 | $11.38 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $10.68B | $10.51B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
GSAT trades at $82.68, down 0.43% with a bullish technical outlook. The company shows strong gross margins at 62.25% but faces profitability challenges with negative net income margins. Recent satellite launches and infrastructure expansion in Greece signal growth potential, though earnings have consistently missed expectations.
Investment outlook remains mixed with 40% analyst buy ratings but persistent losses. Key risks include execution challenges and high valuation multiples. Positive cash flow and strategic developments provide upside catalysts, but profitability improvement is critical for sustained shareholder value.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →